Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Smolen JS, et al. Among authors: han j, han c. Ann Rheum Dis. 2009 Jun;68(6):823-7. doi: 10.1136/ard.2008.090019. Epub 2008 Jul 1. Ann Rheum Dis. 2009. PMID: 18593759 Clinical Trial.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Smolen JS, et al. Among authors: han j, han c. Arthritis Rheum. 2006 Mar;54(3):702-10. doi: 10.1002/art.21678. Arthritis Rheum. 2006. PMID: 16508926 Free article. Clinical Trial.
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, Wagner C, Han J, Westhovens R. Rahman MU, et al. Among authors: han j. Ann Rheum Dis. 2007 Sep;66(9):1233-8. doi: 10.1136/ard.2006.065995. Epub 2007 Mar 28. Ann Rheum Dis. 2007. PMID: 17392352 Free PMC article. Clinical Trial.
Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
Visvanathan S, Marini JC, Smolen JS, Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C. Visvanathan S, et al. Among authors: han j. J Rheumatol. 2007 Jul;34(7):1465-74. Epub 2007 Jun 1. J Rheumatol. 2007. PMID: 17552048 Clinical Trial.
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P. Kremer J, et al. Among authors: han j. Arthritis Rheum. 2010 Apr;62(4):917-28. doi: 10.1002/art.27348. Arthritis Rheum. 2010. PMID: 20131276 Free article. Clinical Trial.
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.
Braun J, Landewé R, Hermann KG, Han J, Yan S, Williamson P, van der Heijde D; ASSERT Study Group. Braun J, et al. Among authors: han j. Arthritis Rheum. 2006 May;54(5):1646-52. doi: 10.1002/art.21790. Arthritis Rheum. 2006. PMID: 16646033 Free article. Clinical Trial.
32,436 results
You have reached the last available page of results. Please see the User Guide for more information.